Breaking Corporate Events, Analysed in Real Time

Biocon Ltd Launches Yesafili Biosimilar in US Market to Address USD 5.89 Billion Opportunity

Biocon Limited has initiated the commercial launch of Yesafili, its interchangeable biosimilar to Eylea, in the United States. The launch addresses a multi-billion dollar market opportunity in ophthalmology, providing a new treatment option for millions of Americans suffering from vision-threatening conditions.

Shilpa Medicare Subsidiary Commissions Integrated ADC GMP Facility in Dharwad

Shilpa Biologicals Private Ltd, a subsidiary of Shilpa Medicare, has commissioned an integrated Antibody-Drug Conjugate (ADC) GMP manufacturing facility in Dharwad. This advanced unit enables the company to offer end-to-end development and production of complex oncology drug substances for the global pharmaceutical market.